Category Archives: Byetta, Januvia/Janumet and Victoza

Subscribe to Byetta, Januvia/Janumet and Victoza RSS Feed

AstraZeneca Settles 84 Byetta Lawsuits

Posted in Byetta, Januvia/Janumet and Victoza

The litigation regarding incretin mimetics, such as Byetta, Januvia/Janumet and Victoza, continues to grow across the country. Byetta (Exenatide), manufactured by Amylin Pharmaceuticals, in association with Eli Lilly and Co., entered the market in 2005 for the treatment of Type 2 diabetes.  Byetta, now sold by Bristol-Myers Squibb and AstraZeneca, is a type of incretin… Continue Reading

New Study Confirms Januvia/Janumet, Byetta and Victoza Linked to Pancreatic Injuries

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, the American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications (Januvia/Janumet/Byetta/Victoza) to make patient level data on their products available for an independent review. Research into the safety of these incretin medications continues across the globe. A recent study published in… Continue Reading

Parties Preparing Consolidated Pleadings in Byetta, Januvia/Janumet and Victoza Litigation

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was centralized… Continue Reading

Status Conference for Byetta, Januvia/Janumet and Victoza Litigation

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was centralized… Continue Reading

ADA Asks for Incretin Mimetic Data

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, recent evidence suggests that incretin mimetic medications are linked to pancreatitis and pancreatic cancer. The American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications to make patient level data on their products available for an independent review. The ADA is concerned… Continue Reading

Transfer Order Consolidates Incretin Mimetic Litigation in Southern California

Posted in Byetta, Januvia/Janumet and Victoza

As we previously reported, the United States Judicial Panel on Multi-District Litigation (MDL) convened to determine whether the cases, known as IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery… Continue Reading

Byetta and Januvia Lawsuits May Soon Be Consolidated

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, safety concerns regarding incretin mimetics such Byetta, Januvia/Janumet and Victoza, have lead to hundreds of lawsuits being filed across the country. Reports suggest that people taking the medications, Januvia and/or Byetta, for the treatment of Type 2 diabetes may be at an increased risk to develop pancreatitis or pancreatic cancer…. Continue Reading

JAMA Study Probes Risk of Pancreatic Disorders from Diabetes Medication

Posted in Byetta, Januvia/Janumet and Victoza, Defective Drugs

As we have previously reported, research has shown that several incretin mimetic pharmaceuticals may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.  The April 8, 2013, edition of the Journal of the American Medical Association Internal Medicine (“JAMA”) published a study… Continue Reading

FDA Meets to Discuss Safety of Diabetes Medications

Posted in Byetta, Januvia/Janumet and Victoza, Defective Drugs

As we have previously reported, research has shown that several incretin mimetic pharmaceuticals, such as Byetta, Januvia/Janumet and Victoza, may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas. Doctors have expressed concern about these drugs and their connection between pancreatitis, pancreatic… Continue Reading

Diabetes Expert Warns Use of Byetta Linked to Pancreatic Cancer

Posted in Byetta, Januvia/Janumet and Victoza

As we have previously reported, litigation regarding incretin mimetics, such as Byetta, Januvia/Janumet and Victoza, continues to grow across the country. Byetta (Exenatide), manufactured by Amylin Pharmaceuticals, in association with Eli Lilly and Co., entered the market in 2005 for the treatment of Type 2 diabetes.  Byetta, now sold by Bristol-Myers Squibb and AstraZeneca, is… Continue Reading

Motion to Consolidate Incretin Mimetic Cases into One Multidistrict Litigation Currently Pending

Posted in Byetta, Januvia/Janumet and Victoza, Defective Drugs

Researchers at Johns Hopkins University have recently determined that a number of incretin mimetic diabetes medications like Byetta, Januvia/Janumet and Victoza could be linked to pancreatitis and pancreatic cancer. A motion to consolidate the incretin mimetic cases into one MDL is currently pending. The Judicial Panel on Multidistrict Litigation (JPML) will likely hear oral argument,… Continue Reading

Incretin Mimetic Medications Byetta, Januvia/Janumet and Victoza Can Cause Substantial Injury

Posted in Byetta, Januvia/Janumet and Victoza, Defective Drugs

There are an estimated 25 million people in the United States with diabetes with an estimated $245 billion a year in diabetes-related health costs.  A number of drugs have been introduced to treat diabetes patients and time has shown that certain types of these drugs can cause substantial injury. Byetta (Exenatide), manufactured by Amylin Pharmaceuticals,… Continue Reading